DNA Testing/Diagnostics Market Size & Forecast Report, 2012 - 2022

The global DNA Testing/Diagnostics Market is anticipated to grow at a staggering CAGR in the forthcoming period. Diagnostic tests are the basis of a successful healthcare system that enables vital information about patients and healthcare providers necessary to land into right decisions.

The drivers for DNA testing market include demand for personalized medicine applications for chronic disorders is likely to propel the market growth. Rise in demand for DNA diagnostics for new born babies adds to the market growth during the forecast period. In addition, genetic testing gains a higher traction to determine patient’s health at different stages of disease development fuels the market growth.

Product segment for DNA testing/diagnostics industry includes service & software, reagents and instruments. By technology, the DNA diagnostics market comprises in-situ hybridization, microarray, PCR, mass spectrometry and sequencing technology. Application segment for DNA testing industry include myogenic disorder and infectious disease. Infectious disease is segmented as Hepatitis B virus, Hepatitis C virus, TB, CT/NG. MRSA and HPV.

Myogenic disorder is further segmented as pre-implantation diagnostics and prenatal diagnostics. Geographical segmentation for DNA testing market includes North America, South America, Europe, Asia-Pacific, Middle East and Africa. North America holds a dominant share in the global market owing to rise in adoption of DNA diagnostics technology and significant prevalence of chronic and infectious disease.

Asia-Pacific market is anticipated to rise at a higher CAGR due to rise in research programs conducted by government in developing economies. Constant R&D and commercialization of technology for treatment of chronic diseases is likely to contribute to the market growth during the forecast period. The key players in the DNA diagnostics industry include Cephide Inc., 454 Life Sciences, Abbott Laboratories, Beckman Coulter Inc., Bio-Rad Laboratories, Hologic, GE Healthcare, Thermo Fisher Scientific, Illumina Inc., TransgenomicInc., Siemens Healthcare, Roche Diagnostics, Qiagen, Illumina, AlereInc, Affymetrix Inc., Agilent Technologies Inc., Dako, and Applied Biosystems Group.

Market Segment:

Global DNA Diagnostics/Testing Technology Outlook (Revenue, USD Million, 2012 - 2022)
    • Microarrays based diagnostics
    • PCR based diagnostics
    • In-situ hybridization diagnostics
    • NGS DNA diagnosis

Global DNA Diagnostics/Testing Application Outlook (Revenue, USD Million, 2012 - 2022)
    • Prenatal DNA Carrier Screening
    • Preimplantation Diagnosis
    • Newborn Genetic Screening
    • Infectious Disease Diagnostics
        • HBV Diagnostic
        • HCV Diagnostic
        • HIV Diagnostic
        • TB Diagnostic
        • CT/NG Diagnostic
        • HPV Diagnostic
        • MRSA Diagnostic
        • Others
    • Oncology Diagnostics & Histopathology
    • Identity Diagnostics & Forensics
    • Pharmacogenomics Diagnostic Testing
    • Drug Metabolism & P450 effects
    • Others

DNA Diagnostics/Testing Regional Outlook (Revenue, USD Million, 2012 - 2022)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • UK
    • Asia Pacific
        • Japan
        • China
    • Latin America
        • Brazil
        • Mexico
    • MEA
        • South Africa